intraday trading

It's a familiar story to anyone who knows much about financial history…   In the decade or so following the greatest spree of money printing and credit growth in history, we witnessed a tremendous bubble in financial assets.   This bubble saw interest rates on government bonds plummet as bond and stock prices soared.   It saw financial innovations no one had ever thought of before, including new ways to organize capital and banking systems.   It even saw the emergence of new currencies, which soared in value, creating an entirely new class of wealth.   Most people had no idea what to make of all of these new financial innovations. They couldn't believe how much wealth was being created. And in the days following a national holiday, huge crowds of investors stampeded to join in this new financial revolution.   Everyone would soon be rich!

intraday trading: U S Concrete, Inc.(USCR)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, basic materials shares fell 0.36 percent. Meanwhile, top losers in the sector included US Concrete Inc (NASDAQ: USCR), down 10 percent, and Commercial Metals Company (NYSE: CMC), down 4 percent.

  • [By WWW.THESTREET.COM]

    Coming up in tonight’s episode of Mad Money: Cramer interviews Bill Sandbrook, CEO of U.S. Concrete (USCR)  and focuses on opportunities for Xilinx (XLNX) .  Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By Lisa Levin]

    In trading on Friday, basic materials shares fell 0.73 percent. Meanwhile, top losers in the sector included US Concrete Inc (NASDAQ: USCR), down 8 percent, and Seabridge Gold, Inc. (USA) (NYSE: SA), down 5 percent.

intraday trading: Tele Celular Sul Participacoes S.A.(TSU)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Monday, telecommunications services shares fell 0.45 percent. Meanwhile, top losers in the sector included Shenandoah Telecommunications Company (NASDAQ: SHEN), down 3 percent, and TIM Participacoes SA (ADR) (NYSE: TSU) down 2 percent.

intraday trading: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $102.47 on Tuesday, down more than 11% compared with Monday’s closing price of $115.42. The stock’s 52-week high is $157.02. Volume totaled more than 16 million shares, nearly 6 times the daily average of about 3 million. The company announced several executive changes this morning.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) tumbled to the bottom of the S&P 500 today after the company’s CEO and CFO left the firm following the delay of its 10-Q last month.

    Getty Images

    Alexion Pharmaceuticals dropped 13% to $115.04 today, while the S&P 500 dipped 0.1% to 2,256.96.

    BMO’s M. Ian Somaiya offers his take on the chaos at Alexion:

    Alexion has delayed its 3Q 10-Q filing as a result of an internal investigation involving the company’s sales practices. The company continues to believe restatement of previously reported results is not required.Alexion expects filing of 3Q 10-Q in January 2017 or earlier, and 4Q/FY2016 earnings in February, when guidance is expected.

    Near-term downside may be priced in, caution on guidance. We believe the announcement of new management adds a new overhang to the stock, but also believe downside may be priced in (Alexion is down ~9% at open) and may provide an opportunity for investors to dip their toes if not their feet. We believe Alexion’s recovery will be driven by its next-generation C5 inhibitor, ALXN-1210, as every-eight-week dosing should enable Alexion to maintain 75% of the PNH market, while SubQ success, depending on dosing schedule/volume, may enable Alexion to do better. Additionally, we believe label extensions for Soliris in rMG, NMO may provide near-term growth drivers. Further upside is dependent on 30 pre-clinical assets in Alexion’s pipeline and the pace of Soliris adoption in MG. We believe the weakness may provide a unique opportunity for accumulation, with potential downside risk related to guidance from new management during 4Q/FY2016 earnings in February.

    Alexion Pharmaceuticals’ market capitalization fell to $25.8 billion today from $29.6 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By David Sterman]

    Growth-oriented investors should also check out Alexion Pharmaceuticals (Nasdaq: ALXN(link is external)), which falls through the cracks between the massive well-established biotechs, and the small-cap biotechs that are still pre-revenue.

    Alexion targets rare and severe diseases, and has built a broad platform of drugs to treat them. Sales growth has never been less than 37% at any point in the past eight years, and 20% to 25% growth appears locked in over coming years as well. Analysts at UBS, who see 30% upside to their $202 price target, believe that a healthy drug pipeline provides multiple catalysts this year in the form of clinical trial updates. They suggest that shares would be worth $230 in a buyout scenario. 

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) soared to the top of the S&P 500 today after its audit committee found no need to restate the company’s financials.

    Agence France-Presse/Getty Images

    Alexion Pharmaceuticalsgained 9.5% to $139.18 today, while the S&P 500 dipped 0.1% to 2,269.00.

    Morgan Stanley’sMatthew Harrison and team argue that the audit committees report is “lifting a cloud” over Alexion, but they still have their concerns:

    Without significant fireworks mgt. has filed the 10-Q lifting a cloud around the details on the potential wrong doing and its impact. While the “pull-in” sales had less than a 1% impact and do not appear pervasive in use as evidenced by the limited amount outside of 4Q15, we do wonder how the increased scrutiny will impact the selling organization and the potential increased conservatism among personnel going forward. We look forward to 2017 guidance and updates to MG filing and 1210 enrollment at the 4Q16 call.

    Alexion’s market capitalization rose to $31.2 billion today from $28.5 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $98.63 on Wednesday, down about 5.7% compared with Tuesday’s closing price of $04.64. The stock’s 52-week high is $157.02. Volume totaled about 8.5 million shares, around 4 times the daily average of about 3 million. The company announced several executive changes on Tuesday and the fallout has continued.

  • [By Ben Levisohn]

    Three biotech stocks–Alexion Pharmaceuticals (ALXN), Amgen (AMGN), and Celgene (CELG)–reported earnings since yesterday’s close. But just one has seen its shares head higher after the announcement.

    Getty Images

    That would be Alexion, which reported a profit of $1.38, beating forecasts for $1.23, according to Reuters, on sales of $870 million, ahead of analyst expectations for $826.6 million. Those results have sent Alexion shares up 5.1% to $126.87 at 34:35 p.m. today.

    Unfortunately, Amgen and Celgene are trading lower, despite beating earnings forecasts. Credit Suisse analystAlethia Young and team call Amgen’s quarter “mixed,” which helps explain why its stock has dropped 1.4% to $162.25. They explain:

    Product revenues were light by $200M although the company raised their bottom line EPS guidance for 2017. Newer product volume growth seemed sound although some legacy products experienced challenges: Reported revenues were $5.46B vs. consensus of $5.57B. EPS beat with $3.15/sh non-GAAP EPS vs. consensus of $3.00/sh driven by lower OpEx spend, specifically with non-GAAP R&D coming in at $748M vs. $900M consensus. We think results for the quarter were mixed, with some notable headwinds on the topline. After listening to the call, it seems the quarter consisted of various one-type dynamics for products where revenues were light (Enbrel and Repatha). Enbrel missed by close to $200M ($1,181M vs. $1,360M consensus) and we think rheumatology/dermatology dynamics (both pricing and volume) remain a focus for investors. Repatha came in at $50M vs. $72M consensus although the company noted last quarter was helped by a one-time bulk order. Neulasta helped on the topline at $1,210M vs. $1,142M consensus although this was helped by some purchases from larger end customers.

    …while Evercore ISI’s Umer Raffat explains why investors were disappointed by Celgene’s earnings beat:

    Celg

intraday trading: LivaNova PLC(LIVN)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Tuesday, our Elite Opportunity Pronewsletter suggested small cap medical technology stock LivaNova PLC (NASDAQ: LIVN):

    From a fundamental perspective, LIVN currently offers investors with a potentially nice opportunity on both a short and long-term basis. With a $2.37B market cap, this pure mid-cap play currently trades at a forward P/E of just over 14 and a five year PEG of just 1.15. The Company is also projected to grow their bottom line from this year to next by as much as 14%

Leave a Reply

Your email address will not be published. Required fields are marked *